someone explain cagrilintide to me like I have not read a paper in years
Genuine question, and the title is the question: someone explain cagrilintide to me like I have not read a paper in years.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Went looking for independent results on this and found a handful across the whole site.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
satiety signalling rather than incretin signalling
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
read the combination arms separately from the monotherapy arms
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
nothing here is approved as a standalone product and research material is not for human use
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
Disagree — you are quoting a combination arm as though it were monotherapy.
hub_ops is right that the evidence base here is thin. Conclusions should be held loosely.
Sent a vial to Medutest because there was almost nothing on file for this compound. 99.2% against a claimed 99.0%, and I posted it because the log needs entries.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Read the combination paper twice before saying anything here.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
the co-agonism argument is about complementary mechanisms
phase 3 data will change most of what gets said here
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
- 1Went looking for independent results on this and found a handful across the…11 comments in this branch · started by u/niels_norgaard